Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares
Objective New-onset immune-mediated inflammatory diseases (IMIDs) and flares of pre-existing IMIDs have been reported following anti- SARS-CoV2 vaccination. Our study aimed at describing a retrospective cohort of patients developing new-onset IMIDs or flares of known IMIDs within 30 days after any a...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-09-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/8/2/e002460.full |
| _version_ | 1811273888869384192 |
|---|---|
| author | Alessia Alunno Francesco Carubbi Davide Grassi Claudio Ferri Jessica Santilli Laura Natali Bernardina Mancini Nicoletta Di Gregorio Rita Del Pinto Angelo Viscido |
| author_facet | Alessia Alunno Francesco Carubbi Davide Grassi Claudio Ferri Jessica Santilli Laura Natali Bernardina Mancini Nicoletta Di Gregorio Rita Del Pinto Angelo Viscido |
| author_sort | Alessia Alunno |
| collection | DOAJ |
| description | Objective New-onset immune-mediated inflammatory diseases (IMIDs) and flares of pre-existing IMIDs have been reported following anti- SARS-CoV2 vaccination. Our study aimed at describing a retrospective cohort of patients developing new-onset IMIDs or flares of known IMIDs within 30 days after any anti-SARS-CoV2 vaccine dose.Methods We evaluated clinical records of all inpatients and outpatients referring to our institution between February 2021 and February 2022 with any clinical manifestations. We then selected those having received any anti-SARS-CoV2 vaccine dose within the prior 30 days and classified them as having or not a previous IMID according to predefined criteria. We recorded new-onset IMIDs or flares of known IMIDs and investigated any relationship with demographic, clinical and serological variables.Results 153 patients that received any anti-SARS-CoV2 vaccine dose within the previous 30 days were included of which 45 (29%) already had a diagnosis of IMID while 108 (71%) had no previously diagnosed IMID. 33 (30%) of the 108 patients, were diagnosed with a new-onset IMID. Pericarditis, polymyalgia rheumatica and vasculitis were the most frequent conditions. Among the 45 patients that already had an IMID, disease flare was the reason for referral in 69% of patients. Patients with an IMID flare had a lower number of comorbidities and tended to be younger compared with those who developed other conditions after anti-SARS-CoV2 vaccination.Conclusion We provided a retrospective overview of a cohort of patients who developed new-onset IMIDs or flares of known IMIDs within 30 days after any dose of anti-SARS-CoV2 vaccine. While vaccination campaigns proceed, postvaccination surveillance programmes are ongoing and hopefully will soon clarify whether a causal relationship between vaccines and new-onset/flares of IMIDs exists. |
| first_indexed | 2024-04-12T23:08:55Z |
| format | Article |
| id | doaj.art-045738da14c44a06b3e892fe845ec58c |
| institution | Directory Open Access Journal |
| issn | 2056-5933 |
| language | English |
| last_indexed | 2024-04-12T23:08:55Z |
| publishDate | 2022-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj.art-045738da14c44a06b3e892fe845ec58c2022-12-22T03:12:51ZengBMJ Publishing GroupRMD Open2056-59332022-09-018210.1136/rmdopen-2022-002460Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flaresAlessia Alunno0Francesco Carubbi1Davide Grassi2Claudio Ferri3Jessica Santilli4Laura Natali5Bernardina Mancini6Nicoletta Di Gregorio7Rita Del Pinto8Angelo Viscido95 Internal Medicine and Nephrology Unit, University of L`Aquila Department of Clinical Medicine Life Health and Environmental Sciences, L`Aquila, Italy5 Internal Medicine and Nephrology Unit, University of L`Aquila Department of Clinical Medicine Life Health and Environmental Sciences, L`Aquila, Italy3 Department of Life, Health, and Environmental Sciences, University of L`Aquila, L`Aquila, Abruzzo, Italy1Department of Life, Health and Environmental Sciences, Division of Internal Medicine and Nephrology, University of L`Aquila, L`Aquila, ItalyDepartment of Life, Health & Environmental Sciences and Internal Medicine and Nephrology Unit, Department of Medicine, University of L`Aquila and ASL Avezzano-Sulmona-L`Aquila, San Salvatore Hospital, L`Aquila, ItalyDepartment of Life, Health & Environmental Sciences and Internal Medicine and Nephrology Unit, Department of Medicine, University of L`Aquila and ASL Avezzano-Sulmona-L`Aquila, San Salvatore Hospital, L`Aquila, ItalyDepartment of Life, Health & Environmental Sciences and Internal Medicine and Nephrology Unit, Department of Medicine, University of L`Aquila and ASL Avezzano-Sulmona-L`Aquila, San Salvatore Hospital, L`Aquila, ItalyDepartment of Life, Health & Environmental Sciences and Internal Medicine and Nephrology Unit, Department of Medicine, University of L`Aquila and ASL Avezzano-Sulmona-L`Aquila, San Salvatore Hospital, L`Aquila, ItalyDepartment of Life, Health & Environmental Sciences and Internal Medicine and Nephrology Unit, Department of Medicine, University of L`Aquila and ASL Avezzano-Sulmona-L`Aquila, San Salvatore Hospital, L`Aquila, ItalyDepartment of Life, Health & Environmental Sciences and Internal Medicine and Nephrology Unit, Department of Medicine, University of L`Aquila and ASL Avezzano-Sulmona-L`Aquila, San Salvatore Hospital, L`Aquila, ItalyObjective New-onset immune-mediated inflammatory diseases (IMIDs) and flares of pre-existing IMIDs have been reported following anti- SARS-CoV2 vaccination. Our study aimed at describing a retrospective cohort of patients developing new-onset IMIDs or flares of known IMIDs within 30 days after any anti-SARS-CoV2 vaccine dose.Methods We evaluated clinical records of all inpatients and outpatients referring to our institution between February 2021 and February 2022 with any clinical manifestations. We then selected those having received any anti-SARS-CoV2 vaccine dose within the prior 30 days and classified them as having or not a previous IMID according to predefined criteria. We recorded new-onset IMIDs or flares of known IMIDs and investigated any relationship with demographic, clinical and serological variables.Results 153 patients that received any anti-SARS-CoV2 vaccine dose within the previous 30 days were included of which 45 (29%) already had a diagnosis of IMID while 108 (71%) had no previously diagnosed IMID. 33 (30%) of the 108 patients, were diagnosed with a new-onset IMID. Pericarditis, polymyalgia rheumatica and vasculitis were the most frequent conditions. Among the 45 patients that already had an IMID, disease flare was the reason for referral in 69% of patients. Patients with an IMID flare had a lower number of comorbidities and tended to be younger compared with those who developed other conditions after anti-SARS-CoV2 vaccination.Conclusion We provided a retrospective overview of a cohort of patients who developed new-onset IMIDs or flares of known IMIDs within 30 days after any dose of anti-SARS-CoV2 vaccine. While vaccination campaigns proceed, postvaccination surveillance programmes are ongoing and hopefully will soon clarify whether a causal relationship between vaccines and new-onset/flares of IMIDs exists.https://rmdopen.bmj.com/content/8/2/e002460.full |
| spellingShingle | Alessia Alunno Francesco Carubbi Davide Grassi Claudio Ferri Jessica Santilli Laura Natali Bernardina Mancini Nicoletta Di Gregorio Rita Del Pinto Angelo Viscido Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares RMD Open |
| title | Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares |
| title_full | Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares |
| title_fullStr | Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares |
| title_full_unstemmed | Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares |
| title_short | Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares |
| title_sort | immune mediated inflammatory diseases after anti sars cov 2 vaccines new diagnoses and disease flares |
| url | https://rmdopen.bmj.com/content/8/2/e002460.full |
| work_keys_str_mv | AT alessiaalunno immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares AT francescocarubbi immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares AT davidegrassi immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares AT claudioferri immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares AT jessicasantilli immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares AT lauranatali immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares AT bernardinamancini immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares AT nicolettadigregorio immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares AT ritadelpinto immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares AT angeloviscido immunemediatedinflammatorydiseasesafterantisarscov2vaccinesnewdiagnosesanddiseaseflares |